OLFM4 Antibody (02) [Janelia Fluor® 635]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-06414JF635
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA
Label
Janelia Fluor 635
Antibody Source
Monoclonal Mouse IgG1 Clone # 02
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human OLFM4 (Accession#: NP_006409.3; Met 1-Gln 510).
Reactivity Notes
No cross-reactivity in ELISA with:
Human cell lysate (293 cell line)
Human cell lysate (293 cell line)
Specificity
No cross-reactivity in ELISA with: Human cell lysate (293 cell line)
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Applications for OLFM4 Antibody (02) [Janelia Fluor® 635]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Olfactomedin-4/OLFM4
Alternate Names
GC1, GW112, OlfD, OLFM4, OLM4
Gene Symbol
OLFM4
Additional Olfactomedin-4/OLFM4 Products
Product Documents for OLFM4 Antibody (02) [Janelia Fluor® 635]
Product Specific Notices for OLFM4 Antibody (02) [Janelia Fluor® 635]
Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...